Literature DB >> 33855783

O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43's mRNA splicing activity.

Meng-Jie Zhao1, Xiao Yao2, Ping Wei3, Chen Zhao2, Meng Cheng2, Dong Zhang2, Wen Xue4,5, Wen-Tian He6, Weili Xue2, Xinxin Zuo2, Lei-Lei Jiang6, Zhiyuan Luo7, Jiaqi Song2, Wen-Jie Shu2, Han-Ye Yuan2, Yi Liang2, Hui Sun2, Yan Zhou7, Yu Zhou2, Ling Zheng2, Hong-Yu Hu6, Jiwu Wang4,5,8, Hai-Ning Du2.   

Abstract

Pathological TDP-43 aggregation is characteristic of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP); however, how TDP-43 aggregation and function are regulated remain poorly understood. Here, we show that O-GlcNAc transferase OGT-mediated O-GlcNAcylation of TDP-43 suppresses ALS-associated proteinopathies and promotes TDP-43's splicing function. Biochemical and cell-based assays indicate that OGT's catalytic activity suppresses TDP-43 aggregation and hyperphosphorylation, whereas abolishment of TDP-43 O-GlcNAcylation impairs its RNA splicing activity. We further show that TDP-43 mutations in the O-GlcNAcylation sites improve locomotion defects of larvae and adult flies and extend adult life spans, following TDP-43 overexpression in Drosophila motor neurons. We finally demonstrate that O-GlcNAcylation of TDP-43 promotes proper splicing of many mRNAs, including STMN2, which is required for normal axonal outgrowth and regeneration. Our findings suggest that O-GlcNAcylation might be a target for the treatment of TDP-43-linked pathogenesis.
© 2021 The Authors.

Entities:  

Keywords:  O-GlcNAcylation; RNA splicing; TDP-43; neurodegeneration

Mesh:

Substances:

Year:  2021        PMID: 33855783      PMCID: PMC8183420          DOI: 10.15252/embr.202051649

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   9.071


  53 in total

1.  The ALS-associated proteins FUS and TDP-43 function together to affect Drosophila locomotion and life span.

Authors:  Ji-Wu Wang; Jonathan R Brent; Andrew Tomlinson; Neil A Shneider; Brian D McCabe
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

2.  The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine.

Authors:  C S Arnold; G V Johnson; R N Cole; D L Dong; M Lee; G W Hart
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

3.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

Review 4.  O-GlcNAc signalling: implications for cancer cell biology.

Authors:  Chad Slawson; Gerald W Hart
Journal:  Nat Rev Cancer       Date:  2011-08-18       Impact factor: 60.716

5.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Kenji Ikeda; Takashi Nonaka; Hiroshi Mori; David Mann; Kuniaki Tsuchiya; Mari Yoshida; Yoshio Hashizume; Tatsuro Oda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-30       Impact factor: 3.575

6.  Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo.

Authors:  Edor Kabashi; Li Lin; Miranda L Tradewell; Patrick A Dion; Valérie Bercier; Patrick Bourgouin; Daniel Rochefort; Samar Bel Hadj; Heather D Durham; Christine Vande Velde; Guy A Rouleau; Pierre Drapeau
Journal:  Hum Mol Genet       Date:  2009-12-03       Impact factor: 6.150

7.  CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.

Authors:  Nicole F Liachko; Pamela J McMillan; Chris R Guthrie; Thomas D Bird; James B Leverenz; Brian C Kraemer
Journal:  Ann Neurol       Date:  2013-07-08       Impact factor: 10.422

8.  TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.

Authors:  Jemeen Sreedharan; Ian P Blair; Vineeta B Tripathi; Xun Hu; Caroline Vance; Boris Rogelj; Steven Ackerley; Jennifer C Durnall; Kelly L Williams; Emanuele Buratti; Francisco Baralle; Jacqueline de Belleroche; J Douglas Mitchell; P Nigel Leigh; Ammar Al-Chalabi; Christopher C Miller; Garth Nicholson; Christopher E Shaw
Journal:  Science       Date:  2008-02-28       Impact factor: 47.728

9.  Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping.

Authors:  E Buratti; T Dörk; E Zuccato; F Pagani; M Romano; F E Baralle
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

10.  ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair.

Authors:  Joseph R Klim; Luis A Williams; Francesco Limone; Irune Guerra San Juan; Brandi N Davis-Dusenbery; Daniel A Mordes; Aaron Burberry; Michael J Steinbaugh; Kanchana K Gamage; Rory Kirchner; Rob Moccia; Seth H Cassel; Kuchuan Chen; Brian J Wainger; Clifford J Woolf; Kevin Eggan
Journal:  Nat Neurosci       Date:  2019-01-14       Impact factor: 24.884

View more
  3 in total

Review 1.  Regulation of Cellular Ribonucleoprotein Granules: From Assembly to Degradation via Post-translational Modification.

Authors:  Pureum Jeon; Hyun-Ji Ham; Semin Park; Jin-A Lee
Journal:  Cells       Date:  2022-06-29       Impact factor: 7.666

2.  O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43's mRNA splicing activity.

Authors:  Meng-Jie Zhao; Xiao Yao; Ping Wei; Chen Zhao; Meng Cheng; Dong Zhang; Wen Xue; Wen-Tian He; Weili Xue; Xinxin Zuo; Lei-Lei Jiang; Zhiyuan Luo; Jiaqi Song; Wen-Jie Shu; Han-Ye Yuan; Yi Liang; Hui Sun; Yan Zhou; Yu Zhou; Ling Zheng; Hong-Yu Hu; Jiwu Wang; Hai-Ning Du
Journal:  EMBO Rep       Date:  2021-04-15       Impact factor: 9.071

Review 3.  O-GlcNAcylation in health and neurodegenerative diseases.

Authors:  Byeong Eun Lee; Pann-Ghill Suh; Jae-Ick Kim
Journal:  Exp Mol Med       Date:  2021-11-26       Impact factor: 8.718

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.